Adoptive Cell Therapy for Sarcoma

"This clinical trial is open to 10 people aged 18-39 with sarcoma who meet the following criteria: Eastern Cooperative Oncology Group (ECOG) 0 to 1; ECOG performance status of 0 to 1 inferred if patient's energy level is ≥ 50% of baseline; negative pregnancy test for women of childbearing potential at screening; willingness and availability to comply with all study procedures, as well as having progressed on one standard prior care treatment regimen."

"Unfortunately, this medical trial has closed its recruitment period; it was initially noticed on September 27th 2019 and went through a final editing process on November 10th 2022. However, there are currently 443 clinical trials for sarcoma patients and 901 TIL studies that can accept participants."

"At the present time, there are 901 research studies that are utilizing TIL as part of their protocol. Out of these trials, 161 have entered Phase 3 testing. Of these 161 trails, most are located in Philadelphia but they span 28476 sites across the globe."

"TIL is often used to mitigate multiple sclerosis, but it also has applications for acute leukemia, myelocytic lymphoma, retinoblastoma, and histiocytosis."

"TIL's safety is presumed to be high, as it has only been in the first phase of clinical trials. Thus, our analysis assigns a score of 1 for this drug’s safety profile."

"Unfortunately, this particular study has ceased recruitment of patients. It was originally made available on September 27th 2019 and the last changes were recorded November 10th 2022. However, there are currently 443 clinical trials actively seeking sarcoma patient participants as well as 901 recruiting for TIL therapy."

"The requirements for this clinical trial necessitate that participants must be between 18-39 years old. By contrast, there are 468 trials available to those below the age of consent and 1041 studies appropriate for individuals older than 65."